Insight

Manni Mohyuddin: Why striving for MRD negativity at all costs and having MRD as a primary endpoint may not be ideal

Photo taken from Manni Mohyuddin/X

Feb 23, 2024, 14:39

Manni Mohyuddin: Why striving for MRD negativity at all costs and having MRD as a primary endpoint may not be ideal

Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared on X/Twitter:

“Why striving for MRD negativity at all costs and having MRD as a primary endpoint may not be ideal:

In this randomized three-arm trial, the arm with the best MRD negativity rate had the worst overall survival!

One of the most important take-home messages from ASH23!

The pursuit of MRD negativity is neither necessary, nor safe for a substantial proportion of (older/less fit) patients with multiple myeloma, who experience prolonged disease control/excellent quality of life with lesser levels of response.

This is a fact that is often omitted from the discussion. Link to study.”

Source: Manni Mohyuddin/X

ASH23 cancer Huntsman Cancer Institute Manni Mohyuddin MRD MRD negativity multiple myeloma OncoDaily Oncology take-home messages from ASH23 University of Utah

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer